Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for LGND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -62.70M
March 31, 2026 -7.654M
December 31, 2025 -9.298M
September 30, 2025 -78.13M
June 30, 2025 -8.239M
March 31, 2025 -4.222M
December 31, 2024 -56.48M
September 30, 2024 -21.40M
June 30, 2024 -9.552M
March 31, 2024 -15.30M
December 31, 2023 -6.526M
September 30, 2023 -7.574M
June 30, 2023 -9.11M
March 31, 2023 0.762M
December 31, 2022 -1.401M
September 30, 2022 -6.742M
June 30, 2022 5.258M
March 31, 2022 -0.347M
December 31, 2021 8.264M
September 30, 2021 -1.898M
June 30, 2021 -1.091M
March 31, 2021 -20.59M
December 31, 2020 4.153M
September 30, 2020 -0.909M
June 30, 2020 -1.129M
Date Value
March 31, 2020 72.87M
December 31, 2019 82.18M
September 30, 2019 178.08M
June 30, 2019 37.59M
March 31, 2019 152.58M
December 31, 2018 98.91M
September 30, 2018 -7.011M
June 30, 2018 -42.10M
March 31, 2018 -7.021M
December 31, 2017 1.313M
September 30, 2017 -1.494M
June 30, 2017 -2.015M
March 31, 2017 -0.355M
December 31, 2016 2.094M
September 30, 2016 -2.628M
June 30, 2016 -1.469M
March 31, 2016 -0.511M
December 31, 2015 -1.47M
September 30, 2015 -1.46M
June 30, 2015 -4.649M
March 31, 2015 -0.781M
December 31, 2014 28.99M
September 30, 2014 26.41M
June 30, 2014 -0.453M
March 31, 2014 -3.195M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Johnson & Johnson -138.00M
Eli Lilly & Co. 1.601B
Merck & Co., Inc. 714.00M
Zevra Therapeutics, Inc. -0.435M
Liquidia Corp. -1.443M